Skip to main content
Erschienen in: Supportive Care in Cancer 6/2009

01.06.2009 | Original Article

The palliative performance scale: examining its inter-rater reliability in an outpatient palliative radiation oncology clinic

verfasst von: Sarah Campos, Liying Zhang, Emily Sinclair, May Tsao, Elizabeth A. Barnes, Cyril Danjoux, Arjun Sahgal, Philiz Goh, Shaelyn Culleton, Gunita Mitera, Edward Chow

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The Palliative Performance Scale (PPS) was developed by the Victoria Hospice Society in 1996 to modernize the Karnofsky Performance Scale. Currently, it is being used to measure palliative patient performance status in a variety of settings. Despite its widespread use, only one study has examined the inter-rater reliability of the PPS.

Purpose

To examine the inter-rater reliability of the PPS in measuring performance status in patients seen in an outpatient palliative radiation oncology clinic

Methods

Performance status for 102 consecutive patients was assessed by an oncologist (MD), a radiation therapist (RT), and a research assistant (RA) in the Rapid Response Radiotherapy Program at the Odette Cancer Centre in Toronto, Ontario, Canada. Raters’ scores were analyzed for correlation and compared to evaluate the inter-rater reliability of the PPS tool.

Results

Excellent correlation was found between the scores rated by the MD and RA (r = 0.86); good correlation was observed between scores rated by the MD and RT (r = 0.69) and the RT and RA (r = 0.77). Scores between all three raters, as well as between rater pairs, were also found to have good reliability as measured by the Chronbach’s alpha coefficient. Significant results were obtained for the range of PPS scores in which the majority of our patients fell: 40–80%.

Conclusion

PPS was shown to have good overall inter-rater reliability in an outpatient palliative setting, but more research is needed to establish the validity and reliability of the tool in a variety of different palliative settings.
Literatur
2.
Zurück zum Zitat Anderson F, Downing GM, Hill J, Casorso L, Lerch N (1996) Palliative performance scale (PPS): a new tool. J Palliat Care 12(1):5–11PubMed Anderson F, Downing GM, Hill J, Casorso L, Lerch N (1996) Palliative performance scale (PPS): a new tool. J Palliat Care 12(1):5–11PubMed
3.
Zurück zum Zitat de Miguel Sanchez C, Elustondo SG, Estirado A, Sanchez FV, de la Rasilla Cooper CG, Romero AL et al (2006) Palliative performance status, heart rate and respiratory rate as predictive factors of survival time in terminally ill cancer patients. J Pain Symptom Manage 31(6):485–492 doi:10.1016/j.jpainsymman.2005.10.007 PubMedCrossRef de Miguel Sanchez C, Elustondo SG, Estirado A, Sanchez FV, de la Rasilla Cooper CG, Romero AL et al (2006) Palliative performance status, heart rate and respiratory rate as predictive factors of survival time in terminally ill cancer patients. J Pain Symptom Manage 31(6):485–492 doi:10.​1016/​j.​jpainsymman.​2005.​10.​007 PubMedCrossRef
6.
Zurück zum Zitat Olajide O, Hanson L, Usher BM, Qaqish BF, Schwartz R, Bernard S (2007) Validation of the palliative performance scale in the acute tertiary care hospital setting. Journal of Palliative Medicine 10(1):111–117 February 1, 2007PubMedCrossRef Olajide O, Hanson L, Usher BM, Qaqish BF, Schwartz R, Bernard S (2007) Validation of the palliative performance scale in the acute tertiary care hospital setting. Journal of Palliative Medicine 10(1):111–117 February 1, 2007PubMedCrossRef
8.
Zurück zum Zitat Harrold J, Rickerson E, Carroll JT, McGrath J, Morales K, Kapo J et al (2005) Is the palliative performance scale a useful predictor of mortality in a heterogeneous hospice population? J Palliat Med 8(3):503–509 doi:10.1089/jpm.2005.8.503 PubMedCrossRef Harrold J, Rickerson E, Carroll JT, McGrath J, Morales K, Kapo J et al (2005) Is the palliative performance scale a useful predictor of mortality in a heterogeneous hospice population? J Palliat Med 8(3):503–509 doi:10.​1089/​jpm.​2005.​8.​503 PubMedCrossRef
11.
Zurück zum Zitat Lau F, Cloutier-Fisher D, Kuziemsky C, Black F, Downing M, Borycki E et al (2007) A systematic review of prognostic tools for estimating survival time in palliative care. J Palliat Care 23(2):93–112PubMed Lau F, Cloutier-Fisher D, Kuziemsky C, Black F, Downing M, Borycki E et al (2007) A systematic review of prognostic tools for estimating survival time in palliative care. J Palliat Care 23(2):93–112PubMed
12.
Zurück zum Zitat Cancer Care Ontario (2006) Palliative Care Strategy: Improving the quality of palliative care services for cancer patients in Ontario. Cancer Care Ontario, Toronto October Cancer Care Ontario (2006) Palliative Care Strategy: Improving the quality of palliative care services for cancer patients in Ontario. Cancer Care Ontario, Toronto October
13.
Zurück zum Zitat de Borja M, Chow E, Bovett G, Davis L, Gillies C (2004) The correlation among patients and health care professionals in assessing functional status using the Karnofsky and eastern cooperative oncology group performance status scales. Support Cancer Ther 2(1):59–63 doi:10.3816/SCT.2004.n.024 PubMedCrossRef de Borja M, Chow E, Bovett G, Davis L, Gillies C (2004) The correlation among patients and health care professionals in assessing functional status using the Karnofsky and eastern cooperative oncology group performance status scales. Support Cancer Ther 2(1):59–63 doi:10.​3816/​SCT.​2004.​n.​024 PubMedCrossRef
15.
Zurück zum Zitat Roila F, Lupattelli M, Sassi M, Basurto C, Bracarda S, Picciafuoco M et al (1991) Intra and interobserver variability in cancer patients’ performance status assessed according to Karnofsky and ECOG scales. Ann Oncol 2(6):437–439PubMed Roila F, Lupattelli M, Sassi M, Basurto C, Bracarda S, Picciafuoco M et al (1991) Intra and interobserver variability in cancer patients’ performance status assessed according to Karnofsky and ECOG scales. Ann Oncol 2(6):437–439PubMed
16.
Zurück zum Zitat Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2(3):187–193PubMed Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2(3):187–193PubMed
17.
Zurück zum Zitat Sorensen JB, Klee M, Palshof T, Hansen HH (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67(4):773–775PubMed Sorensen JB, Klee M, Palshof T, Hansen HH (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67(4):773–775PubMed
Metadaten
Titel
The palliative performance scale: examining its inter-rater reliability in an outpatient palliative radiation oncology clinic
verfasst von
Sarah Campos
Liying Zhang
Emily Sinclair
May Tsao
Elizabeth A. Barnes
Cyril Danjoux
Arjun Sahgal
Philiz Goh
Shaelyn Culleton
Gunita Mitera
Edward Chow
Publikationsdatum
01.06.2009
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0524-z

Weitere Artikel der Ausgabe 6/2009

Supportive Care in Cancer 6/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.